Combined Approaches for Drug Design Points the Way to Novel Proline Racemase Inhibitor Candidates to Fight Chagas' Disease

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Berneman, Armand ^a   Montout, Lory ^a   Goyard, Sophie ^a   Chamond, Nathalie ^a,c   Cosson, Alain ^a   d'Archivio, Simon ^a   Gouault, Nicolas ^b   Uriac, Philippe ^b   Blondel, Arnaud ^a   Minoprio, Paola ^a  

^a INSTITUT PASTEUR   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRROLECARBOXYLIC ACID; 4 BROMOPYRAZOLE 3 CARBOXYLIC ACID; 4 CHLORO 5 METHYLPYRAZOLE 3 CARBOXYLIC ACID; 4 CHLOROPYRAZOLE 3 CARBOXYLIC ACID; 4 ETHYLPYRAZOLE 3 CARBOXYLIC ACID; 4 OXOPENT 2 ENOIC ACID; 5 BROMO 4 OXOPENT 2 ENOIC ACID; ENZYME INHIBITOR; PYRAZOLE 3 CARBOXYLIC ACID; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL DIFFERENTIATION; CELL FATE; CHAGAS DISEASE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG BINDING; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME CONFORMATION; MOLECULAR DOCKING; MOLECULAR WEIGHT; PROCESS DEVELOPMENT;

AMINO ACID ISOMERASES; CHAGAS DISEASE; DRUG DESIGN; ENZYME INHIBITORS; PROTEIN STRUCTURE, SECONDARY; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

HEXAPODA; MAMMALIA; PROTOZOA; RUMEX; TRYPANOSOMA CRUZI;

EID: 84876173494     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060955     Document Type: Article

References (48)

1. O'Connell D, (2007) Neglected Diseases. Nature 449: 157.
2. Salvatella R, (2007) Andean subregional Chagas disease area and the Andean initiative of Chagas disease. Mem Inst Oswaldo Cruz 102Suppl 1: 39-40.
3. Aznar C, La Ruche G, Laventure S, Carme B, Liegeard P, et al. (2004) Seroprevalence of Trypanosoma cruzi infection in French Guiana. Mem Inst Oswaldo Cruz 99: 805-808.
4. CDCP (2006) Chagas Disease After Organ Transplantation - Los Angeles, California, 2006. 798-200 p.
5. CDCP (2007) Blood Donor Screening for Chagas Disease - United States, 2006-2007. 141-143 p.
6. Garraud O, Andreu G, Elghouzzi MH, Laperche S, Lefrere JJ, (2007) Measures to prevent transfusion-associated protozoal infections in non-endemic countries. Travel Med Infect Dis 5: 110-112.
7. Chamond N, Coatnoan N, Minoprio P, (2002) Immunotherapy of Trypanosoma cruzi infections. Curr Drug Targets Immune Endocr Metabol Disord 2: 247-254.
8. Coura JR, De Castro SL, (2002) A Critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 97: 3-24.
9. Docampo R, (1990) Sensitivity of parasites to free radical damage by antiparasitic drugs. Chem Biol Interact 73: 1-27.
10. Maya JD, Bollo S, Nunez-Vergara LJ, Squella JA, Repetto Y, et al. (2003) Trypanosoma cruzi: effect and mode of action of nitroimidazole and nitrofuran derivatives. Biochem Pharmacol 65: 999-1006.
11. WHO web site (2013) Research Priorities for Chagas Disease, Human African Trypanosomiasis and Leishmaniasis. Available: http://www.who.int/tdr/publications/research_priorities/en/. Accessed 2013 March 8.
12. Morel C, Carvalheiro J, Romero C, Costa E, Buss P, (2007) Neglected diseases: the road to recovery. Nature 449: 180-182.
13. Reina-San-Martin B, Cosson A, Minoprio P, (2000) Lymphocyte polyclonal activation: a pitfall for vaccine design against infectious agents. Parasitol Today 16: 62-67.
14. Chamond N, Gregoire C, Coatnoan N, Rougeot C, Freitas LH, da Silveira JF, Degrave WM, Minoprio P, (2003) Biochemical characterization of proline racemases from the human protozoan parasite Trypanosoma cruzi and definition of putative protein signatures. J Biol Chem 278: 15484-15494.
15. Chamond N, Goytia M, Coatnoan N, Barale JC, Cosson A, et al. (2005) Trypanosoma cruzi proline racemases are involved in parasite differentiation and infectivity. Mol Microbiol 58: 46-60.
16. Keenan MV, Alworth WL, (1974) The inhibition of proline racemase by a transition state analogue: delta-1-pyrroline-2-carboxylate. Biochem Biophys Res Commun 57: 500-504.
17. Coutinho L, Ferreira MA, Cosson A, Batista MM, Batista Dda G, et al. (2009) Inhibition of Trypanosoma cruzi proline racemase affects host-parasite interactions and the outcome of in vitro infection. Mem Inst Oswaldo Cruz 104: 1055-1062.
18. Buschiazzo A, Goytia M, Schaeffer F, Degrave W, Shepard W, et al. (2006) Crystal structure, catalytic mechanism, and mitogenic properties of Trypanosoma cruzi proline racemase. Proc Natl Acad Sci U S A 103: 1705-1710.
19. Chamond N, Gregoire C, Coatnoan N, Rougeot C, Freitas-Junior LH, et al. (2003) Biochemical characterization of proline racemases from the human protozoan parasite Trypanosoma cruzi and definition of putative protein signatures. J Biol Chem 278: 15484-15494.
20. Gouault N, Pinel B, Cupif JF, Depince A, Martin-Chouly CA, et al. (2004) Synthesis and potential anti-inflammatory activity of some tetrahydrophthalazinones. J Enzyme Inhib Med Chem 19: 475-480.
21. Fatin-Rouge N, Toth E, Perret D, Backer RH, Merbach AE, et al. (2000) Lanthanide podates with programmed intermolecular interactions: luminescence enhancement through association with cyclodextrins and unusually large relaxivity of the gadolinium self-aggregates. J Am Chem Soc 122: 10810-10820.
22. Kubota H, Okazaki H, Onuma M, Kano S, Hattori M, et al. (1992) CD3+4-8- ab T cell population with biased T cell receptor V gene usage. Presence in bone marrow and possible involvelment of IL-3 for their extrathymic development. J Immunol 149: 1143-1150.
23. Manaev YA, Andreeva MA, Perevalov VP, Stepanov BI, Dubrovskaya VA, et al. (1982) Syntheses from dimethylpyrazole V. Nitration of-3-and-5-carboxylic acids. J. Gen. Chem. USSR (EnglTransl) 52: 2291-2296 See Chem. Abstr. 2298: 71993.
24. Janin YL, (2010) Synthetic axxesses to 3/5-pyrazole carboxylic acids. Mini-reviews in Organic Chemistry 7: 342-353.
25. Laine E, Goncalves C, Karst JC, Lesnard A, Rault S, et al. (2010) Use of allostery to identify inhibitors of calmodulin-induced activation of Bacillus anthracis edema factor. Proc Natl Acad Sci U S A 107: 11277-11282.
26. Fischer S, Karplus M, (1992) Conjugate Peak Refinement: an algorithm for finding reaction paths and accurate transition states in systems with many degrees of freedom. Chemical Physics Letters 194: 252-261.
27. Brooks BR, Brooks CL 3rd, Mackerell AD Jr, Nilsson L, Petrella RJ, et al (2009) CHARMM: the biomolecular simulation program. J Comput Chem 30: 1545-1614.
28. Schaefer M, Karplus M, (1996) A comprehensive analytical treatment of continnum electrostatics. Journal of Physical Chemistry 100: 1578-1599.
29. Taly A, Colas C, Malliavin T, Blondel A, Nilges M, et al. (2011) Discrimination of agonists versus antagonists of nicotinic ligands based on docking onto AChBP structures. J Mol Graph Model 30: 100-109.
30. Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14: 33-38, 27-38.
31. Rarey M, Kramer B, Lengauer T, Klebe G, (1996) A fast flexible docking method using an incremental construction algorithm. J Mol Biol 261: 470-489.
32. Molecular-Networks-Inspiring-Chemical-Discovery website (2013) CORINA- Fast Generation of High-Quality 3D Molecular Models. Available: http://www.molecular-networks.com/products/corina. Accessed 2013 March 8.
33. Abagyan R, Totrov M, Kuznetsov D, (1994) ICM-A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation. Journal of Computational Chemistry 15: 488-506.
34. Berneman A, Alves-Ferreira M, Coatnoan N, Chamond N, Minoprio P, (2010) Medium/High Throughput D-Amino Acid Oxidase Colorimetric Method for Determination of D-Amino Acids. Application for Amino Acid Racemases. J Microbial Biochem Technol 2: 139-146.
35. de Souza EM, Araujo-Jorge TC, Bailly C, Lansiaux A, Batista MM, et al. (2003) Host and parasite apoptosis following Trypanosoma cruzi infection in in vitro and in vivo models. Cell Tissue Res 314: 223-235.
36. da Silva CF, Batista MM, Batista Dda G, de Souza EM, da Silva PB, et al. (2008) In vitro and in vivo studies of the trypanocidal activity of a diarylthiophene diamidine against Trypanosoma cruzi. Antimicrob Agents Chemother 52: 3307-3314.
37. Corsano S, Capito L, Bonamico M, (1958) Research on the structure of glutinic acid. I. Heterocyclic derivatives of the allenic acids. Ann Chim (Rome) 48: 140-155.
38. Blondel A, Renaud JP, Fischer S, Moras D, Karplus M, (1999) Retinoic acid receptor: a simulation analysis of retinoic acid binding and the resulting conformational changes. J Mol Biol 291: 101-115.
39. Osorio L, Rios I, Gutierrez B, Gonzalez J, (2012) Virulence factors of Trypanosoma cruzi: who is who? Microbes Infect (14) (): 1390-402.
40. Bryan MA, Norris KA, (2010) Genetic immunization converts the Trypanosoma cruzi B-Cell mitogen proline racemase to an effective immunogen. Infect Immun 78: 810-822.
41. Lee GM, Craik CS, (2009) Trapping moving targets with small molecules. Science 324: 213-215.
42. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, et al. (1983) CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. Journal of Computational Chemistry 4: 187-217.
43. Appel A, (2011) Drugs: More shots on target. Nature 480: S40-42.
44. Kwong AD, Kauffman RS, Hurter P, Mueller P, (2011) Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol 29: 993-1003.
45. Robertson JG, (2005) Mechanistic basis of enzyme-targeted drugs. Biochemistry 44: 5561-5571.
46. Singh J, Petter RC, Baillie TA, Whitty A, (2011) The resurgence of covalent drugs. Nat Rev Drug Discov 10: 307-317.
47. Chamond N, Cosson A, Coatnoan N, Minoprio P, (2009) Proline racemases are conserved mitogens: characterization of a Trypanosoma vivax proline racemase. Mol Biochem Parasitol 165: 170-179.
48. Goytia M, Chamond N, Cosson A, Coatnoan N, Hermant D, et al. (2007) Molecular and structural discrimination of proline racemase and hydroxyproline-2-epimerase from nosocomial and bacterial pathogens. PLoS ONE 2: e885.